Small Molecules
Total Trials
12
As Lead Sponsor
10
As Collaborator
2
Total Enrollment
3,579
NCT03009734
Evaluation of ATx201 as a Topical Antibiotic Agent
Phase: Phase 1/2
Role: Lead Sponsor
Start: Dec 31, 2016
Completion: Mar 31, 2018
NCT03304470
A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis
Phase: Phase 2
Start: Sep 25, 2017
Completion: Mar 5, 2018
NCT03301870
A Study to Evaluate the Irritation Potential of ATx201 in Healthy Volunteers
Phase: Phase 1
Start: Oct 4, 2017
Completion: Nov 6, 2017
NCT03375957
Sensitization Study of ATx201 in Healthy Volunteers
Start: Jan 8, 2018
Completion: Mar 15, 2018
NCT03429595
Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo
Start: Feb 23, 2018
Completion: Jun 26, 2018
NCT04339985
Study to Evaluate Safety & Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults With Mild to Moderate AD
Start: Oct 22, 2019
Completion: Mar 31, 2021
NCT04576312
Safety of Ascending Doses of Niclosamide (UNI911 INHALATION) in Healthy Volunteers
Start: Jun 29, 2020
Completion: Dec 4, 2020
NCT04870333
PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V
Phase: Phase 2/3
Role: Collaborator
Start: Feb 19, 2021
Completion: Apr 16, 2025
NCT04932915
Safety and Efficacy of Intranasal Administration of Niclosamide (UNI91103) in Adults With Asymptomatic or Mild COVID-19
Start: Sep 3, 2021
Completion: Jan 10, 2022
NCT04982432
Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa
Start: Oct 1, 2021
Completion: Dec 1, 2022
NCT05190419
Study to Assess the Efficacy and Safety of Orismilast in Psoriasis
Start: Dec 30, 2021
Completion: Dec 20, 2022
NCT05469464
Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)
Start: Jul 11, 2022
Completion: Feb 15, 2024
Loading map...